Curis (CRIS) reported quarterly earnings results on Monday, May-9-2016. The company said it had a profit of $-0.07 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.01. Analysts had a consensus of $-0.08. The company posted revenue of $1.73 million in the period, compared to analysts expectations of $2.36 million. The company’s revenue was up 1.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.30 EPS.
Many Wall Street Analysts have commented on Curis. Sun Trust Rbsn Humphrey Initiated Curis on Mar 2, 2016 to “Buy”, Price Target of the shares are set at $3.
Curis (CRIS) witnessed a volatile trading activity on Friday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $1.81 and reached the intraday high at $1.9. The bulls started the profit booking and pushed the shares to intraday low of $1.76. The trading session was marked by a volume range of 3,01,345 shares exchanging hands. The 52-week high of the shares is $3.75 and the 52-week low is $1.25. The market cap of the company stands at $231 M and there are 12,90,22,028 shares in public circulation.
In a different news, on Dec 30, 2015, Daniel R Passeri (director) sold 25,600 shares at $2.96 per share price.
Curis Inc. (Curis) is a biotechnology company. The Company is engaged in the development and commercialization drug candidates for the treatment of human cancers. The Company’s drug candidate CUDC-907 is an orally available small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Curis’ product pipeline also includes CUDC-427 an orally available small molecule antagonist of inhibitor of apoptosis (IAP) proteins. CUDC-907 is in Phase I clinical trial stage for the treatment of advanced lymphomas and multiple myeloma and human epidermal growth factor receptor 2 (HER 2-) estrogen-receptor-positive (ER+) or progesterone-receptor-positive (PR+) breast cancer and NUT midline carcinoma. CUDC-427 is in Phase I clinical trial stage for the treatment of advanced solid tumor and lymphomas. The Company’s PD-L1 antagonist and IRAK4 Inhibitor drug candidates are in preclinical stage of development.